
Oncorus ONCR
Quartalsbericht 2023-Q1
hinzugefügt 22.05.2023
Oncorus EBITDA per Share 2011-2026 | ONCR
EBITDA per Share Jährlich Oncorus
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.81 K | -2.48 K | -5.88 | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -5.88 | -2.81 K | -1.77 K |
EBITDA per Share Vierteljährlich Oncorus
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.1 | - | -0.67 | - | -0.67 | - | -0.6 | -0.61 | -0.51 | - | -7.69 | -8.11 | -7.67 K | - | -7.34 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -0.51 | -7.67 K | -769 |
EBITDA per Share anderer Aktien in der Pharmaeinzelhändler
| Name | EBITDA per Share | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-0.71 | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
0.08 | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-1.05 | $ 0.8 | -3.79 % | $ 36.6 M | ||
|
Exelixis
EXEL
|
3.32 | $ 46.1 | -5.34 % | $ 12.5 B | ||
|
Athira Pharma
ATHA
|
-23.7 | - | - | $ 269 M | ||
|
Fortress Biotech
FBIO
|
-2.5 | $ 2.42 | -4.96 % | $ 67.5 M | ||
|
Heron Therapeutics
HRTX
|
-0.06 | $ 1.23 | -6.11 % | $ 205 M | ||
|
Ionis Pharmaceuticals
IONS
|
-1.28 | $ 75.89 | -1.26 % | $ 12.1 B | ||
|
BioNTech SE
BNTX
|
62.6 | $ 92.94 | -2.44 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-2.84 | - | - | $ 231 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
0.69 | $ 211.16 | -9.2 % | $ 3.86 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.4 | $ 22.45 | 4.49 % | $ 3.72 B | ||
|
Mirum Pharmaceuticals
MIRM
|
0.04 | $ 101.38 | -7.9 % | $ 5.09 B | ||
|
MannKind Corporation
MNKD
|
0.17 | $ 3.64 | 2.11 % | $ 1.11 B | ||
|
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | ||
|
Matinas BioPharma Holdings
MTNB
|
-1.27 | $ 0.65 | -4.01 % | $ 3.56 M | ||
|
Esperion Therapeutics
ESPR
|
0.29 | $ 3.15 | - | $ 655 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-6.03 | $ 3.6 | 7.46 % | $ 5.93 M | ||
|
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M | ||
|
Nanobiotix S.A.
NBTX
|
-1.49 | $ 42.99 | 2.7 % | $ 286 B | ||
|
Genprex
GNPX
|
-264 | $ 0.87 | -2.16 % | $ 811 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
-2.19 | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-3.02 | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-0.09 | $ 20.92 | -13.47 % | $ 2.66 B | ||
|
Allena Pharmaceuticals
ALNA
|
-0.696 | - | 3.16 % | $ 1.9 M | ||
|
Genmab A/S
GMAB
|
10.4 | $ 27.08 | -2.9 % | $ 16.7 B | ||
|
Ampio Pharmaceuticals
AMPE
|
0.15 | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
-1.72 | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-1.99 | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
-0.77 | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
-1.92 | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-1.57 | - | 17.91 % | $ 11.1 M |